Medical News: ENDO: Sorafenib Active in Advanced Thyroid Cancer - in Meeting Coverage, ENDO from MedPage Today

Links shared publicly online about this topic.

  • 1,958
    total visits

Medical News: ENDO: Sorafenib Active in Advanced Thyroid Cancer - in Meeting Coverage, ENDO from MedPage Today

medpagetoday.com —

WASHINGTON -- Two-thirds of patients with advanced thyroid cancer benefited from treatment with the tyrosine kinase inhibitor sorafenib (Nexavar), data from a small clinical trial showed.

View full resource at medpagetoday.com

Tags: Cancer, Thyroid Cancer, Clinical Trial, News, Medical

  • Share

Most Recently Shared on June 19, 2009 at 4:44 pm By:

ONClive Editor

Phase II trial of sorafenib (Nexavar) showed activity in advanced thyroid cancer. http://www.medpagetoday.com/MeetingCoverage/ENDO/14783

3 years ago...

Reply

Retweet

Favorite

Also Shared By:

Medical News Medical News

Advertisement